Gaorong Capital is a venture capital firm specializing in early and growth-stage investments, primarily in China. Their investment focus spans new consumption, new technology (including AI and frontier technologies), enterprise services, and healthcare sectors, with a strong emphasis on TMT. The firm positions itself as "China's Founders' Fund," aiming to be a strategic partner for entrepreneurs driving innovation and industry transformation.
Portfolio
8
Fund Size
$4B
Top Stage
Series A
Last 12 Mo
1
Team
JY
Jiangtao Yu
Managing Director
BY
Bin Yue
Partner
Stage Distribution
Portfolio
8 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| MAI | Seed | $25M | Sep 2025 |
| Pulnovo Medical | Series C | — | Mar 2025 |
| HashKey Group | Series B | $30M | Feb 2025 |
| HashKey Group | Growth | $30M | Feb 2025 |
| Allink Biotherapeutics | Series A | $42M | Nov 2024 |
| Dongchedi | Growth | $600M | Sep 2024 |
| ProfoundBio | Series A | $55M | Jul 2021 |
| XTransfer | Series A | $10M | Oct 2018 |
Top Co-Investors
Lilly Asia Ventures2 shared
General Atlantic1 shared
Hongshan1 shared
KKR & Co.1 shared
OrbiMed1 shared
LYFE Capital1 shared
Sequoia China1 shared
K2VC1 shared
Kleiner Perkins1 shared
UpHonest Capital1 shared
Yunqi Partners1 shared
Legend Capital1 shared
Last updated: 1 March 2026